CAS
BCRX icon

CTC Alternative Strategies’s BioCryst Pharmaceuticals BCRX Stock Holding History

CTC Alternative Strategies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-11,900
Closed -$18.4K – 101
2013
Q2 		$18.4K Buy
+11,900
New +$20.5K 0.01% 198

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CTC Alternative Strategies's BCRX Position: Q3 2013 in Review

CTC Alternative Strategies sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2013, closing a stake of 11,900 shares — an estimated $18.4K sold.

CTC Alternative Strategies first reported a position in BCRX in Q2 2013 and held it in 1 quarter. The position peaked at $18.4K in Q2 2013. 73 funds tracked by Wall St. Rank hold BCRX as of Q3 2013.

  • CTC Alternative Strategies reported no remaining BioCryst Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • CTC Alternative Strategies sold 11,900 BioCryst Pharmaceuticals shares in Q3 2013, an estimated $18.4K.
  • CTC Alternative Strategies first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • CTC Alternative Strategies's BioCryst Pharmaceuticals position peaked at $18.4K in Q2 2013.
  • 73 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2013.

Based on CTC Alternative Strategies's 13F filing for Q3 2013, filed 31 Oct 2013.